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Abstract: Although long considered to be cellular debris, microparticles (MPs) are more 
recently considered reﬂ  ective of cellular stimulation, activation, and degeneration/apoptosis. 
MPs that arise from the cellular components of blood and the endothelial lining of blood ves-
sels are referred to as blood MPs and by general consensus are small (1.5 μm), expose the 
anionic phospholipid (PL) phosphatidylserine (PS) on the outer leaﬂ  et of their membrane, and 
bear surface membrane antigens reﬂ  ecting their cellular origin. This brief review summarizes 
the different approaches used by several groups to study blood MPs. The aim of this article is 
to review the technical aspects of characterizing the morphological and functional properties 
of blood MPs with emphasis on the preanalytical and analytical variables involved in these 
studies.
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Introduction
Cellular microparticles (MPs) are fragments of the plasma membrane that are shed by 
virtually all cell when subject to a number of stress conditions, including cellular activa-
tion and apoptosis (Beaudoin and Grondin 1991; Zwaal and Schroit 1997; Freyssinet 
et al 1999; Hugel et al 2005). Since the description of “platelet dust” by Wolf (1967), 
numerous studies have reported the presence of subcellular vesicles in centrifuged plasma. 
Although long considered to be cellular debris, blood MPs are more recently considered 
reﬂ  ective of cellular stimulation, activation, and degeneration/apoptosis (Freyssinet 
2003; Morel et al 2005; Boulanger et al 2006). By general consensus, MPs are small in 
size (1.5 μm), expose the anionic phospholipid (PL) phosphatidylserine (PS) on the 
outer leaﬂ  et of their membrane, and bear surface membrane antigens reﬂ  ecting their 
cell of origin (Jy et al 2004). MPs that arise from the cellular components of blood and 
the endothelial lining of blood vessels are referred to as blood MPs. Apart from blood 
MPs, plasma contains smaller membrane vesicles (40–100 nm) termed exosomes and 
larger vesicles (1.5 μm) termed apoptotic bodies that are derived from blood and 
vascular cells (Heijnen et al 1999; Freyssinet 2003). The aim of this article is to review 
the technical aspects of characterizing the morphological and functional properties of 
blood MPs with emphasis on both preanalytical and analytical variables.
Membrane phospholipid asymmetry 
and microparticle formation
All cell type’s spontaneously shed blebs from their plasma membranes in an active 
process that appears to be important for membrane remodeling and antigenic turn-
over. In resting cells, the negatively charged phospholipids, including PS, are almost 
exclusively present in the inner leaﬂ  et of the cell membrane (Zwaal and Schroit 1997). 
Among the mechanisms proposed to account for this asymmetry are unidirectional 
enzymatic movement by an aminophospholipid translocase and/or association between Vascular Health and Risk Management 2008:4(4) 770
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the negatively charged phospholipids and elements in the 
cytoplasm, including cytoskeletal elements and their accom-
panying proteins (Bevers et al 1998). MP release is an integral 
part of the cell membrane remodeling process whereby the 
normal asymmetric distribution of phospholipids between the 
two leaﬂ  ets of the plasma membrane is lost. Calcium entry, 
activation of calpain and scramblase activity are thought 
to be important steps in the loss of lipid asymmetry and 
microparticle formation, but the exact sequence of events is 
not completely understood (Fox et al 1990; Yano et al 1994; 
Dachary-Prigent et al 1995, 1997; Pasquet et al 1996, 1998; 
Bucki et al 1998, 2006; Kunzelmann-Marche et al 2001). 
The possible pathways leading to membrane budding and 
MP release have been recently reviewed (Freyssinet 2003; 
Boulanger et al 2006).
Membrane shedding by blood cells
Erythrocytes
Shedding processes are found in a variety of blood cells 
(Beaudoin and Grondin 1991). Human erythrocytes treated 
with ionophore A23187 in the presence of calcium, respond 
by budding to release MPs. Normal erythrocytes also release 
MPs following ATP depletion, heat treatment (49 °C), 
incubation at pH 5.4 and incubation with diamide (5 mMol/L) 
(Wagner et al 1986). Erythrocyte MPs are also found to be 
elevated in several pathological conditions associated with 
hemolysis (Hugel et al 1999) but are notably elevated in 
sickle cell anemia (Allan et al 1982). Erythrocyte-derived 
MPs are usually identiﬁ  ed by the binding of antibodies to 
glycophorin A (CD235a), a protein uniquely expressed on 
the erythrocyte membrane.
White blood cells
These cells have a unique physiological role in inﬂ  ammation, 
immune regulation, and thrombosis. Following exposure to 
various stimuli including lipopolysaccharide and phorbol 
myrisitate, monocytes are observed to vesiculate and release 
MPs (Satta et al 1994; Mesri and Altieri 1999). Monocytes 
express CD14, the lipopolysaccharide receptor strongly on 
their surface while granulocytes express CD14 weakly. Thus, 
monocyte-derived MPs have been identiﬁ  ed by the surface 
expression of CD14. MPs derived from neutrophils have been 
identiﬁ  ed in the blood of normal subjects and in patients with 
meningoccocal sepsis (Nieuwland et al 2000). Typically, 
polymorphonuclear neutrophilic leukocyte-derived MPs are 
identiﬁ  ed using the leukocyte-speciﬁ  c markers lactoferrin 
or CD66b. Lymphocyte-derived MP have been identiﬁ  ed 
using lymphocyte-speciﬁ  c markers CD4 and CD8 (Arm-
strong et al 1988; Aupeix et al 1997; Diamant et al 2002; 
Martin et al 2004).
Platelets
Microparticle formation in platelets occurs as a result 
of activation by various stimuli (epinephrine, adenosine 
diphosphate, collagen, thrombin, A23187) (Horstman and 
Ahn 1999) and during storage (Bode et al 1991). Increased 
platelet MP formation has been documented in a variety 
of clinical conditions that are associated with platelet 
activation (Solum 1999). Platelet-derived MPs that express 
surface glycoproteins and antibodies to CD41, CD42, and 
CD61 have been used to detect platelet-derived MPs (Lee 
et al 1996; Combes et al 1997; Diamant et al 2002). CD61 
is less speciﬁ  c as a platelet marker since this integrin is 
also expressed on blood monocytes and antibodies that 
recognize on the CD61 epitope will identify both platelet- 
and monocyte-derived MPs.
Endothelial cells
Endothelial cells undergo injury and vesiculation following 
in vitro exposure to complement, thrombin and a variety of 
agents such as ionophore, lipopolysaccharide, autoantibodies, 
and cytokines (interleukin-1 and tumor necrosis factor-α) 
(Hamilton et al 1990; Combes et al 1999). Elevated endo-
thelial MPs have been documented in several pathological 
situations including atherosclerosis, sepsis, and diabetes 
mellitus. Several endothelial speciﬁ  c antibodies have been 
used to detect MPs in these situations including CD31, CD51, 
CD105, CD144, and CD146 (Sabatier et al 2002). Of this 
extensive list, CD144 and CD146 are endothelial-speciﬁ  c 
markers as they have not yet been found expressed on any 
other blood cell in humans.
Assays to characterize 
microparticles
In general, most assays have focused on characterizing 
the antigenic composition of cellular microparticles 
using antibody capture-based ELISA (Aupeix et al 1997; 
Freyssinet et al 1999; Mallat et al 1999) or ﬂ  ow cytometry 
(Combes et al 1997, 1999). Most investigators have elected 
to characterize blood MPs using ﬂ  ow cytometry and the 
technical protocols of some have been reviewed in a recent 
forum (Jy et al 2004). In addition to analyzing MP antigens, 
several investigators have assessed the coagulant function 
of blood microparticles using functional assays (Westerman 
et al 1984; Mallat et al 1999; Berckmans et al 2001; Joop 
et al 2001; Shet et al 2003; Aras et al 2004). These assays Vascular Health and Risk Management 2008:4(4) 771
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either measure acceleration of plasmatic coagulation by MP-
derived phospholipids or triggering of plasmatic coagulation 
by MP-associated tissue factor. The PF3 assay, in which 
exposure of platelet poor plasma to Russell’s viper venom 
in the presence of calcium causes coagulation, but only in 
the presence of certain phospholipids (supplied by blood 
MPs), has also been used as a functional assay (Hardisty 
and Hutton 1965).
Preanalytical variables
The measurement of blood MPs requires careful attention to 
collection and processing of blood samples. While there have 
been some general guidelines regarding preanalytical vari-
ables that may be important, these have been more consensus-
driven statements rather than guidelines based on scientiﬁ  c 
evidence. Furthermore, several aspects of blood collection 
such as venepuncture needle size, use of a tourniquet during 
blood collection, phlebotomy using a vacutainer vs a syringe, 
and the type of anticoagulant used (sodium citrate vs eth-
ylenediaminetetraacetic acid) could have an impact on the 
measurement of blood MPs. Additionally, sample processing 
following blood collection is extremely variable between 
investigators and could be partially responsible for the 
discrepancies in blood MPs levels reported in the literature. 
While separating the cellular elements of blood from the 
plasma containing MPs, careful attention must be paid to 
centrifugation speed. In our experience, a 2-step centrifuga-
tion using 1500 × g for 10 minutes and then 13,000 × g for 
10 minutes resulted in platelet-free plasma (when assessed 
by ﬂ  ow cytometry and light microscopy) (Shet et al 2003). 
The second centrifugation step is particularly efﬁ  cient at 
rendering plasma relatively “platelet free” by eliminating 
small platelets but it is unclear if large bloods MPs are also 
depleted in this process. There are several difﬁ  culties in sepa-
rating platelets, microparticles, exosomes, and cellular debris 
as individual components. We have attempted to isolate 
blood MPs from platelet-poor plasma by using a high-speed 
centrifugation step. However, the sample that we work with 
contains exosomes. Isolating blood MPs from exosomes by 
centrifugation is technically challenging and the need for 
such separation is probably dependent on the nature of the 
study being performed.
Analytical variables
Flow cytometry
Flow cytometric analysis of blood MPs appears to be the 
most favored method to characterize blood MPs (Jy et al 
2004). Typically, MPs are identiﬁ  ed as particles with a 
forward angle light scatter (FALS) smaller than an internal 
standard consisting of 1–1.5 μm sized latex particles (Shet 
et al 2003). Most investigators do not use a lower size limit 
but some have arbitrarily chosen 100 nm below which 
particles that are recognized by the instrument are not 
considered MPs (Boulanger et al 2006). Others have used 
platelets as an internal standard and gated particles with a 
FALS value below that of the smallest platelet (Nieuwland 
et al 2000). While the identiﬁ  cation of MPs on the basis 
of size using FALS tests the limit of sensitivity of ﬂ  ow 
cytometry, some have overcome this problem by adjust-
ing the parameters of the instrument to detect ﬂ  uorescent 
intensity (Horstman et al 1994). Flow cytometry can also be 
used to enumerate blood MPs by adding a known number of 
ﬂ  uorescent or nonﬂ  uorescent latex particles to the sample 
prior to performing analysis (Combes et al 1997, 1999; Shet 
et al 2003). The number of MPs present in the sample is 
derived by dividing the number of MP events counted by 
the volume of the sample analyzed, ie, (beads counted/beads 
added) × sample volume, and adjusting for the ﬁ  nal dilu-
tion of the original blood sample. Alternatively, if the ﬂ  ow 
cytometry instrument delivers the sample to the optics cell 
by screw-driven syringe at a known rate, then the sample 
MP count can theoretically be calculated. This method of 
enumeration is less desirable since it makes assumptions 
regarding the instruments ﬂ  uidics and has unacceptable 
day-to-day variability (Reverter et al 1996).
Antibody capture assays
ELISA-based MP capture assays have been devised and 
tested to simplify and semi-automate the characterization 
of blood MPs. These assays have utilized annexin V as a 
means of capturing phospholipids (Aupeix et al 1997; Mallat 
et al 1999) or antibodies to speciﬁ  c blood MP membrane 
antigens, eg, αIIbβ3 (Mallat et al 2000), or antibodies to 
nonspeciﬁ  c blood MP membrane antigens that are shared 
by several cell types eg, antibody 1B5 (Aras et al 2004) 
and have been reviewed elsewhere (Freyssinet et al 1999). 
Such assays have reduced the challenges of analyzing large 
sample numbers.
Other assays
In addition to the above techniques, the antigenic char-
acteristics and the membrane composition of blood MPs 
have been studied using electron microscopy (Heijnen 
et al 1999; Aras et al 2004) (Figure 1 and Figure 2), con-
focal microscopy (Combes et al 1999), high performance 
liquid chromatography (Weerheim et al 2002), capillary Vascular Health and Risk Management 2008:4(4) 772
Shet
electrophoresis (Xiong et al 2003), and mass spectrometry 
(Jin et al 2005; Miguet et al 2006) with varying degrees of 
success. Assays that measure the pro/anticoagulant functions 
of blood MPs are somewhat under-utilized perhaps in part 
due to the technical challenges in developing standardized 
and reproducible assays.
Limitations
Flow cytometry provides useful information about blood 
MPs but there are some limitations associated with this tech-
nique that are worth considering. The deﬁ  nition of a blood 
MP using ﬂ  ow cytometry is still an area of great debate. 
In our studies, we used somewhat rigid criteria to deﬁ  ne 
blood MPs in order to preserve speciﬁ  city while sacriﬁ  cing 
sensitivity to a certain extent. Blood MPs were deﬁ  ned as 
particles that were 1. Removable from platelet-free plasma 
by ultracentrifugation; 2. Were small in size (1μm); and 3. 
Labeled with annexin V. While such criteria may be possible 
in certain situations, they are not practical or possible in all 
conditions. For instance, most would agree that blood MPs 
demonstrate surface PS as evidenced by annexin V labeling, 
but clearly not all plasma particles 1 μm label with annexin 
V (Shet et al 2003; Boulanger et al 2006). Furthermore, a 
substantial portion of plasma particles 1 μm label with 
antibodies to cell surface markers, but not annexin V, which 
suggests that there are PS (−) blood MPs (Shet et al 2003). 
An alternative explanation could be that the exposure of 
PS on the outer aspect of some blood MPs is incomplete 
resulting in absent/reduced annexin V labeling or that some 
MPs contain scramblase activity. Finally, the contribution 
of exosomes and apoptotic bodies to the ﬂ  ow cytometric 
signal obtained cannot be completely ignored. Thus, while 
a consensus ﬂ  ow cytometric deﬁ  nition of blood MPs would 
have utility, one should be aware of the limitations of such 
deﬁ  nitions when studying biological processes. Modern 
ﬂ  ow cytometers are equipped with less powerful lasers and 
have a threshold for particle size detection ∼500 nm below 
which sensitivity is unpredictable according to instrument 
manufacturers (Becton Dickenson, San Jose, CA; pers 
comm). Detecting MPs using ﬂ  uorescence as the primary 
detection parameter has overcome this problem to a certain 
extent, but most investigators do not clearly indicate instru-
ment setting in their description of the methods. Finally, the 
choice of well-characterized antibodies directed against a 
cell membrane antigen that not shared by other cell lineages 
present in blood is an important prerequisite to characterizing 
the cellular origin of blood MPs. Such antibodies should be 
primarily labeled with a ﬂ  ourophore, as the use of secondary 
antibodies is not recommended.
Microparticles in health and disease
The general consensus is that plasma levels of blood MPs 
reﬂ  ect equilibrium between their release and their clearance 
by monocytes-macrophage system. Since clearance of cells 
undergoing apoptosis or injury is extremely efﬁ  cient, the 
Figure 1 Ultrastructure of blood MPs from a patient with sickle cell anemia using 
electron microscopy.
Figure 2 Immunogold labeling of blood MPs. Blood MPs obtained by ultracentrifugation 
were incubated with rabbit polyclonal anti-tissue factor antibody (a; 6 nm gold), anti-
CD144 antibody (b; 12 nm gold), and anti-CD14 antibody (c; 12 nm gold). No labeling 
was observed with control antibodies (d, e, and f ).
Note: Bars = 100 nm.Vascular Health and Risk Management 2008:4(4) 773
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presence of blood MPs is considered an objective in vitro 
parameter that serves as evidence of deleterious cellular 
alterations in vivo. However, very little is published about 
the clearance and fate of blood MPs in any speciﬁ  c disease 
state leaving one to speculate that their presence reﬂ  ects 
either a defect in recognition of these particles or an over-
whelming of the clearance mechanism by their sheer number 
(Willekens et al 2005). Experimental evidence both in vitro 
and in vivo has demonstrated that blood MPs are capable of 
inﬂ  uencing diverse biological function (Zwaal and Schroit 
1997; Barry and FitzGerald 1999; Horstman and Ahn 1999; 
Mesri and Altieri 1999; Freyssinet 2003; Hugel et al 2005; 
Boulanger et al 2006). Blood MPs have been associated with 
several disease processes and while they seem to be useful 
markers there is insufﬁ  cient evidence to demonstrate that 
this association is causal. Clearly, elevated blood MPs in 
several disease processes result from inﬂ  ammation, cellular 
activation and apoptosis. Such MPs, through their diverse 
biological effects, unequivocally contribute to vascular 
disease and comorbidity and are therefore likely to be very 
important in the disease process.
Conclusion
Several studies clearly demonstrate that blood MPs could 
be mediators of disease in some cases, markers of disease 
in other cases, and have prognostic potential, but the patho-
physiological relevance of blood MPs is still in its infancy. 
Many of the studies mentioned in this review demonstrate that 
detection, phenotypic characterization, and quantiﬁ  cation of 
blood MPs are interesting and potentially valuable in patients 
that are at risk for vascular events. However, conversion of 
this potential into a reality will necessitate a standardized 
approach to the detection and characterization of blood MP. 
In addition, attention to the preanalytical and analytical 
variables and reﬁ  nement in the techniques used to assess 
the cellular origin of blood MPs could help shed light on the 
mechanisms of MP release, function, and clearance.
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